[Antihistaminics. Side effects also after raising dosage at the placebo level].
D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002090:Butyrophenones / Q000009:adverse effects / Q000627:therapeutic use*; D017332:Cetirizine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy
D018926:Anti-Allergic Agents; D001562:Benzimidazoles; D002090:Butyrophenones; D006634:Histamine H1 Antagonists; D039563:Histamine H1 Antagonists, Non-Sedating; D010880:Piperidines; D010919:Placebos; C076170:mizolastine; D017336:Loratadine; C058249:ebastine; D017332:Cetirizine